41073-25-0

Basic information

• Product Name: 2-(4-iodo-phenyl)-propionic acid methyl ester
• Synonyms: 2-(4-iodo-phenyl)-propionic acid methyl ester
• CAS NO: 41073-25-0
• Molecular Weight: 290.101
• Mol File: 41073-25-0.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 2-(4-iodo-phenyl)-propionic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-iodo-phenyl)-propionic acid methyl ester(41073-25-0)
• EPA Substance Registry System: 2-(4-iodo-phenyl)-propionic acid methyl ester(41073-25-0)

Safety Data

• Hazardous Substances Data: 41073-25-0(Hazardous Substances Data)

Upstream product

• 19910-33-9 2-(4-nitrophenyl)propanoic acid 
• 50415-69-5 methyl 2-(4-nitrobenzene)propionate 
• 39718-97-3 methyl 2-(4-aminophenyl)propanoate 
• 74-88-4 methyl iodide 
• 1798-06-7 (4-iodophenyl)acetic acid 
• 63349-52-0 methyl 4-iodophenylacetate 

Downstream Products

• 182500-82-9 methyl 2-[4-(4-hydroxybutyl)phenyl]propionate 
• 1441255-95-3 2-(4-{1 [2-(cyclopentyl-methyl-amino)-pyrimidin-4-yl]-piperidin-4-yl}-phenyl)-N-ethyl-propionamide 
• 1441257-15-3 4-[4-(1-methoxycarbonyl-ethyl)-phenyl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 1441257-21-1 4-[4-(1-methoxycarbonyl-ethyl)-phenyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 1441257-09-5 N-ethyl-2-(4-piperidin-4-yl-phenyl)-propionamide 
• 1441257-06-2 N-ethyl-2-(4-pyridin-4-yl-phenyl)-propionamide 
• 1441256-07-0 2-{4-[1-(2-ethoxy-pyrimidin-4-yl)-piperidin-4-yl]-phenyl}-N-ethyl-propionamide 
• 1441255-26-0 N-cyclopropyl-2-{4-[1-(4-ethoxy-phenyl)-piperidin-4-yl]-phenyl}-propionamide 
• 1441255-10-2 2-{4-[1-(2-cyano-4-cyclopropylmethoxy-phenyl)-piperidin-4-yl]-phenyl}-N-cyclopropyl-propionamide 
• 1441255-02-2 2-{-4-[1-(4-cyclopropylmethoxy-2-methoxy-phenyl)-piperidin-4-yl]-phenyl}-N-ethyl-propionamide 
• 1441254-49-4 2-{-4-[1-(4-ethoxy-phenyl)-piperidin-4-yl]-phenyl}-N-ethyl-propionamide 
• 1441257-58-4 2-{4-[1-(4-ethoxy-phenyl)-piperidin-4-yl]-phenyl}-propionic acid 
• 1441257-46-0 2-{4-[1-(2-chloro-pyrimidin-4-yl)-piperidin-4-yl]-phenyl}-N-ethyl-propionamide 
• 1441257-42-6 2-(4-piperidin-4-yl-phenyl)-propionic acid methyl ester 

Relevant articles and documents

Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies

Non-steroidal anti-inflammatory drugs (NSAIDs) exert their pharmacological effects by inhibiting cyclooxygenase (COX)-1 and COX-2. Though widely prescribed for pain and inflammation, these agents have limited utility in chronic diseases due to serious mechanism-based adverse events such as gastrointestinal damage. Concomitant blockade of fatty acid amide hydrolase (FAAH) enhances the therapeutic effects of the NSAIDs while attenuating their propensity to cause gastrointestinal injury. This favorable interaction is attributed to the accumulation of protective FAAH substrates, such as the endocannabinoid anandamide, and suggests that agents simultaneously targeting COX and FAAH might provide an innovative strategy to combat pain and inflammation with reduced side effects. Here, we describe the rational design and structure-active relationship (SAR) properties of the first class of potent multitarget FAAH-COX inhibitors. A focused SAR exploration around the prototype 10r (ARN2508) led to the identification of achiral (18b) as well as racemic (29a-c and 29e) analogs. Absolute configurational assignment and pharmacological evaluation of single enantiomers of 10r are also presented. (S)-(+)-10r is the first highly potent and selective chiral inhibitor of FAAH-COX with marked in vivo activity, and represents a promising lead to discover novel analgesics and anti-inflammatory drugs.

METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B

The invention provides methods for treating an individual having a retinoid responsive disorder. In one embodiment, a method involves administering to the individual an effective amount of a selective CYP26B inhibitor, the selective CYP26B inhibitor having at least 10-fold selectivity for CYP26B relative to CYP26A. In another embodiment, a method involves administering to the individual an effective amount of a selective CYP26A inhibitor, the selective CYP26A inhibitor having a chemical formula set forth in the specification. The invention further provides screening methods for identifying a selective CYP26A inhibitor or selective CYP26B inhibitor.

Seryl-lysyl-based peptide and peptidomimetic inhibitors of N-myristoyl transferase as anti-infective agents

Seryl-lysyl-based peptide and peptidomimetic compounds are described as inhibitors of the enzyme N-myristoyl transferase to provide selective control of the fungal organism Candida albicans. Peptidomimetic compounds of particular interest are those of the formula: STR1 wherein R1 is selected form aminoalkyl, p-aminoalkylphenylalkyl, imidazolylalkylphenylalkyl, 2-alkylimidazolylalkylphenylalkyl, benzimidazolylalkylphenylalkyl and 2-alkylbenzimidazolylalkylphenylalkyl; wherein R2 is selected from hydrido, alkyl, cycloalkyl, akenyl, alkynyl, haloalkyl, benzyl, alkylphenylalkyl, alkoxyphenylalkyl, halophenylalkyl, phenethyl, cycloalkylalkyl, halocycloalkylalkyl, alkylcycloalkylalkyl, alkoxycycloalkylalkyl and naphthylalkyl; wherein Y is selected from carboxylic acid, hydroxamic acid, phosphonic acid and tetrazolyl; or a pharmaceutically-acceptable salt, amide or ester thereof. Compounds of the formula are species-specific inhibitors of C. albicans with little effect on human NMT enzyme and thus would be useful in treating C. albicans fungal infections in humans.